23. Prion disease
[
3 clinical trials,
5 drugs（DrugBank:
2 drugs),
0 target gene / 0 target pathway ]
Searched query = "Prion disease", "Creutzfeldt Jakob disease", "Gerstmann Straussler Scheinker syndrome", "Fatal familial insomnia", "Kuru disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-022233-28-IT | 20/06/2011 | 25 September 2012 | Fatal familial insomnia: preventive treatment with doxycycline of at risk individuals - Doxycycline in FFI individuals | Subjects born between 1958 and 1969 belonging to the Treviso FFI family, tested previously for Prion D178N/129M mutation MedDRA version: 14.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: BASSADO Pharmaceutical Form: Tablet INN or Proposed INN: DOXYCYCLINE HYCLATE CAS Number: 24390-14-5 Concentration unit: 1X 100 milligrams/millilitre Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | IST. DI RICERCHE FARMACOLOG. M. NEGRI | Authorised | Female: yes Male: yes | Italy | ||||||
| 2 | EUCTR2006-001858-27-IT | 21/06/2006 | 19 March 2012 | A randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of doxycline administered by oral route in patients affected by Creutzfeldt-Jakob disease. - ND | A randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of doxycline administered by oral route in patients affected by Creutzfeldt-Jakob disease. - ND | Creutzfeldt-Jakob Disease. MedDRA version: 9.1 Level: LLT Classification code 10011384 Term: Creutzfeldt-Jakob disease | Trade Name: BASSADO 10CPS 100MG Pharmaceutical Form: Tablet INN or Proposed INN: Doxycycline CAS Number: 24390-14-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | ISTITUTO NEUROLOGICO CARLO BESTA | Authorised | Female: yes Male: yes | Italy | |||||
| 3 | NCT00183092 | April 2005 | 19 October 2017 | CJD (Creutzfeldt-Jakob Disease) Quinacrine Study | Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease | Creutzfeldt-Jakob Disease | Drug: Quinacrine;Drug: Placebo | University of California, San Francisco | National Institute on Aging (NIA) | Not recruiting | 18 Years | N/A | All | 69 | Phase 2 | United States |